https://www.prnewswire.com/news-releases/biolinerx-announces-closing-of-15-4-million-underwritten-public-offering-of-its-american-depositary-shares-and-warrants-300791826.html
BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American...
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it...
of 154 million
https://www.biospace.com/biolinerx-announces-initiation-of-phase-1b-clinical-trial-in-patients-with-acute-respiratory-distress-syndrome-ards-secondary-to-covid-19-and-other-respiratory-viral-infections
BioLineRx Announces Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory...
Nov 18, 2020 - - Investigator-initiated study, led by Wolfson Medical Center, to evaluate Motixafortide in up to 25 patients hospitalized with ARDS - - Results of preliminary...
https://www.prnewswire.com/news-releases/biolinerx-accesses-second-tranche-of-20-million-under-previously-announced-40-million-non-dilutive-debt-financing-agreement-302113022.html
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million...
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
20 millionpreviously announcedbiolinerxaccessessecond
https://www.biospace.com/biolinerx-ltd-s-edp-14-for-treatment-of-severe-and-persistent-asthma-to-enter-the-company-s-main-therapeutic-pipeline-as-bl-9010
BioLineRx Ltd.'s EDP-14, for Treatment of Severe and Persistent Asthma, to Enter the Company's Main...
https://www.prnewswire.co.uk/news-releases/biolinerx-announces-proposed-underwritten-public-offering-of-its-american-depositary-shares-and-warrants-820146875.html
BioLineRx Announces Proposed Underwritten Public Offering of its American Depositary Shares and...
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it...
american depositary sharespublic offering
https://www.fiercebiotech.com/biotech/biolinerx-forges-joint-venture-develop-cancer-candidate-norwegian-biotech
BioLineRx forges joint cancer venture with Norwegian biotech
Sep 29, 2025 - The Israeli drug developer will manage, fund and perform all development activities for GLIX1, a small molecule glioblastoma candidate.
biolinerxforgesjointcancerventure
https://www.prnewswire.com/news-releases/blrx-shareholder-alert-rosen-a-global-and-leading-law-firm-encourages-biolinerx-ltd-investors-to-inquire-about-securities-class-action-investigation--blrx-301711496.html
BLRX SHAREHOLDER ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioLineRx Ltd. Investors...
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential civil securities claims on behalf of...
https://www.benzinga.com/markets/commodities/25/01/42826601/nasdaq-surges-over-200-points-biolinerx-shares-plummet
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet - AEON Biopharma (AMEX:AEON) - Benzinga
200 points
https://www.biospace.com/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020
BioLineRx to Report Third Quarter 2020 Results on November 23, 2020 - BioSpace
Nov 18, 2020 - BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited...
third quarter2020 resultsnovember 23biolinerxreport
https://www.finanznachrichten.de/nachrichten-2026-03/68048823-biolinerx-ltd-biolinerx-announces-initiation-of-phase-1-2a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm-008.htm
BioLineRx Ltd.: BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of...
GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated...
https://www.prnewswire.com/news-releases/biolinerx-to-report-first-quarter-2020-results-on-may-20-2020-301060030.html
BioLineRx to Report First Quarter 2020 Results on May 20, 2020
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will...
first quarter2020 resultsbiolinerxreportmay
https://www.biospace.com/biolinerx-announces-9-0-million-registered-direct-offering
BioLineRx Announces $9.0 Million Registered Direct Offering - BioSpace
May 26, 2020 - BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into...
9 0biolinerxannouncesmillionregistered
https://www.prnewswire.com/news-releases/biolinerx-to-report-second-quarter-2020-results-on-august-6-2020-301103774.html
BioLineRx to Report Second Quarter 2020 Results on August 6, 2020
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will...
second quarter2020 resultsbiolinerxreportaugust
https://www.biospace.com/biolinerx-ltd-announces-closing-of-8-million-offering-of-american-depositary-shares
BioLineRx Ltd. Announces Closing of $8 Million Offering of American Depositary Shares - BioSpace
american depositary sharesbiolinerx ltdof 8
https://www.biospace.com/biolinerx-to-report-2023-annual-financial-results-on-march-26-2024
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 - BioSpace
Mar 20, 2024 - BioLineRx Ltd. today announced it will release its audited financial results for the year ended December 31, 2023 on Tuesday, March 26, 2024, before the U.S....
report 2023financial results
https://www.barchart.com/stocks/quotes/BLRX/news
BLRX News for Biolinerx Ltd ADR - Barchart.com
Latest news headlines for Biolinerx Ltd ADR with market analysis and analyst commentary.
biolinerx ltdnewsadrbarchart
https://www.prnewswire.com/il/news-releases/biolinerx-to-present-at-the-2020-biotech-showcase-300983409.html
BioLineRx to Present at the 2020 Biotech Showcase
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that management...
biolinerxpresent2020biotechshowcase